Clinical trial
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed…
NCT00075634 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075634 |
|---|---|
| Title | Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma |
| Official title | A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | decitabine, doxorubicin hydrochloride, cyclophosphamide, filgrastim, pegfilgrastim, laboratory biomarker analysis, pharmacological study |
| Enrollment | 21 |
| Start date | Dec 1, 2003 |
| Primary completion | Sep 1, 2007 |
| First posted | Jan 12, 2004 |
| Last update posted | Sep 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: